Celyad Oncology SA (CYAD.BR)
EUR 0.71
(-7.42%)
EUR 0.71
(-7.42%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -7.76 Million EUR | 52.13% |
| 2022 | -39.69 Million EUR | 26.46% |
| 2021 | -25.41 Million EUR | -5.73% |
| 2020 | -15.73 Million EUR | 11.87% |
| 2019 | -27.45 Million EUR | 26.54% |
| 2018 | -36.56 Million EUR | -124.21% |
| 2017 | -55.69 Million EUR | 23.87% |
| 2016 | -21.98 Million EUR | 21.39% |
| 2015 | -28.07 Million EUR | -54.32% |
| 2014 | -15.31 Million EUR | -63.51% |
| 2013 | -12.06 Million EUR | -2607.55% |
| 2012 | -12 Million EUR | 106.92% |
| 2011 | -6.36 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.85 Million EUR | 0.0% |
| 2023 FY | - EUR | 47.89% |
| 2023 Q4 | -4.46 Million EUR | 0.0% |
| 2023 Q2 | -5.42 Million EUR | 0.0% |
| 2022 FY | - EUR | 26.46% |
| 2022 Q4 | -12.01 Million EUR | 0.0% |
| 2022 Q2 | -7.6 Million EUR | -1.97% |
| 2022 Q1 | -7.45 Million EUR | 9.91% |
| 2021 Q2 | -6.33 Million EUR | 1.25% |
| 2021 Q4 | -8.27 Million EUR | -36.26% |
| 2021 FY | - EUR | -5.73% |
| 2021 Q1 | -6.41 Million EUR | 0.94% |
| 2021 Q3 | -6.07 Million EUR | 4.14% |
| 2020 FY | - EUR | 11.87% |
| 2020 Q3 | -5.55 Million EUR | 63.58% |
| 2020 Q4 | -6.47 Million EUR | -16.68% |
| 2020 Q2 | -15.24 Million EUR | 0.0% |
| 2019 Q2 | -16.32 Million EUR | -146.39% |
| 2019 FY | - EUR | 26.54% |
| 2019 Q4 | -16.29 Million EUR | 0.0% |
| 2019 Q1 | -6.62 Million EUR | 59.02% |
| 2018 Q2 | -15.16 Million EUR | -67.33% |
| 2018 Q1 | -9.06 Million EUR | 32.15% |
| 2018 FY | - EUR | -124.21% |
| 2018 Q4 | -16.17 Million EUR | 0.0% |
| 2017 Q2 | -11.79 Million EUR | 0.19% |
| 2017 FY | - EUR | 23.87% |
| 2017 Q4 | -13.35 Million EUR | 0.0% |
| 2017 Q1 | -11.82 Million EUR | -98.61% |
| 2016 Q4 | -5.95 Million EUR | 0.0% |
| 2016 FY | - EUR | 21.39% |
| 2016 Q2 | -16.58 Million EUR | -201.78% |
| 2016 Q1 | -5.49 Million EUR | 59.9% |
| 2015 Q4 | -13.7 Million EUR | -95.95% |
| 2015 FY | - EUR | -54.32% |
| 2015 Q3 | -6.99 Million EUR | 52.43% |
| 2015 Q2 | -14.7 Million EUR | -110.21% |
| 2015 Q1 | -6.99 Million EUR | 29.78% |
| 2014 Q1 | -3.89 Million EUR | 40.95% |
| 2014 FY | - EUR | -63.51% |
| 2014 Q4 | -9.96 Million EUR | -156.08% |
| 2014 Q3 | -3.89 Million EUR | 35.18% |
| 2014 Q2 | -6 Million EUR | -54.28% |
| 2013 Q3 | -2.75 Million EUR | 50.39% |
| 2013 Q4 | -6.58 Million EUR | -138.79% |
| 2013 FY | - EUR | -2607.55% |
| 2013 Q1 | -2.75 Million EUR | 0.0% |
| 2013 Q2 | -5.56 Million EUR | -101.56% |
| 2012 Q2 | -314.68 Thousand EUR | 0.0% |
| 2012 FY | - EUR | 106.92% |
| 2012 Q1 | -314.68 Thousand EUR | 0.0% |
| 2012 Q3 | -314.68 Thousand EUR | 0.0% |
| 2012 Q4 | -2.75 Million EUR | -776.66% |
| 2011 Q4 | -314.68 Thousand EUR | 80.37% |
| 2011 Q1 | -1.6 Million EUR | 0.0% |
| 2011 Q2 | -1.6 Million EUR | 0.0% |
| 2011 Q3 | -1.6 Million EUR | 0.0% |
| 2011 FY | - EUR | 0.0% |
| 2010 Q4 | -1.6 Million EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -135.957% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 94.172% |
| Adocia SA | -22.73 Million EUR | 65.85% |
| Aelis Farma SA | -6.34 Million EUR | -22.31% |
| Biophytis S.A. | -13.8 Million EUR | 43.763% |
| Advicenne S.A. | -6.24 Million EUR | -24.327% |
| genOway Société anonyme | 6.35 Million EUR | 222.238% |
| IntegraGen SA | -52.5 Thousand EUR | -14685.822% |
| Medesis Pharma S.A. | -3.84 Million EUR | -101.905% |
| Neovacs S.A. | -8.44 Million EUR | 8.125% |
| NFL Biosciences SA | -4.04 Million EUR | -91.712% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 10803.157% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -170.16% |
| Sensorion SA | -22.31 Million EUR | 65.21% |
| Theranexus Société Anonyme | -7.38 Million EUR | -5.087% |
| TME Pharma N.V. | -5.07 Million EUR | -53.056% |
| Valbiotis SA | -6.95 Million EUR | -11.618% |
| TheraVet SA | -517.33 Thousand EUR | -1400.572% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | 58.961% |
| argenx SE | -199.5 Million EUR | 96.109% |
| BioSenic S.A. | -6.79 Million EUR | -14.229% |
| DBV Technologies S.A. | -79.53 Million EUR | 90.239% |
| Galapagos NV | 51.03 Million EUR | 115.211% |
| Genfit S.A. | -28.05 Million EUR | 72.325% |
| GeNeuro SA | -14.31 Million EUR | 45.78% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | 48.178% |
| Innate Pharma S.A. | -7.57 Million EUR | -2.441% |
| Inventiva S.A. | -101.84 Million EUR | 92.378% |
| MaaT Pharma SA | -19.74 Million EUR | 60.674% |
| MedinCell S.A. | -20.04 Million EUR | 61.274% |
| Nanobiotix S.A. | -34.01 Million EUR | 77.18% |
| Onward Medical N.V. | -35.23 Million EUR | 77.967% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -75.104% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 66.634% |
| Oxurion NV | -16.72 Million EUR | 53.596% |
| Pharming Group N.V. | 4.98 Million EUR | 255.853% |
| Poxel S.A. | -12.17 Million EUR | 36.259% |
| GenSight Biologics S.A. | -21.73 Million EUR | 64.275% |
| Transgene SA | -27.02 Million EUR | 71.274% |
| Financière de Tubize SA | 184.57 Thousand EUR | 4305.97% |
| UCB SA | 1.26 Billion EUR | 100.612% |
| Valneva SE | -64.51 Million EUR | 87.968% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 72.62% |